Celularity Welcomes Richard J. Berman to Its Board
Celularity Inc. (NASDAQ: CELU), an innovative company in regenerative and cellular medicine that focuses on placental-derived allogeneic cell therapies and advanced biomaterial products, has announced the addition of Richard J. Berman to its Board of Directors. Mr. Berman brings over 40 years of experience as a public company director, excelling in venture capital, senior management, and mergers and acquisitions. His vast expertise includes leading both public and private companies, with six achieving market values exceeding one billion dollars in just the last five years.
Mr. Berman's Impressive Career
During his distinguished career, Mr. Berman has held significant roles at renowned firms, including Goldman Sachs. As Senior Vice President at Bankers Trust Company, he was instrumental in establishing the M&A Leveraged Buyout Departments. His remarkable history includes advising on over $4 billion in merger and acquisition transactions, successfully completing more than 300 deals. This wealth of experience will be a tremendous asset to Celularity as it aims to strengthen its strategic growth path.
Insights from Celularity's Leadership
Robert J. Hariri, M.D., Ph.D., the founder, Chairman, and Chief Executive Officer of Celularity, shared his excitement regarding Mr. Berman’s appointment. He stated, “I am thrilled to welcome Richard Berman to the Celularity Board of Directors. He brings a unique depth of experience and leadership in guiding public companies and assisting them in building and executing their growth strategies.”
Mr. Berman's Aspirations for Celularity
Reflecting on his new role, Mr. Berman said, “I am eager to collaborate with Dr. Hariri and his team at Celularity as they implement the Company's focused and disciplined growth plan.” His dedication to innovation and strategic expansion resonates with Celularity's mission to provide groundbreaking regenerative therapies.
About Celularity Inc.
Celularity Inc. (NASDAQ: CELU) is a pioneer in regenerative and cellular medicine. The company is committed to the development and commercialization of advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies. What sets Celularity apart from its competitors is its emphasis on therapeutic programs that target aging-related diseases, such as degenerative diseases, cancer, and immune disorders. This is accomplished through the use of mesenchymal-like adherent stromal cells (MLASCs), CAR T-cells, and both genetically modified and unmodified natural killer (NK) cells.
Innovative Therapeutic Approaches
By leveraging the unique properties of placental biology, Celularity strives to create effective, accessible, and affordable therapies that address significant unmet medical needs. The company is dedicated not only to advancing treatment options but also to ensuring these solutions are available to a wider range of patients.
Contact Information for Investors and Media
Investor Contact:
Carlos Ramirez
Senior Vice President, Celularity Inc.
Email: Carlos.ramirez@celularity.com
Media Contact:
Raquel Cona / Michaela Fawcett
KCSA Strategic Communications
Email: rcona@kcsa.com / mfawcett@kcsa.com
Frequently Asked Questions
Who is Richard J. Berman?
Richard J. Berman is an experienced director with over 40 years in venture capital and mergers and acquisitions, recently appointed to the Board of Directors of Celularity Inc.
What role will Mr. Berman play at Celularity?
In his capacity as a board member, Mr. Berman will leverage his extensive expertise to guide the company’s strategic growth initiatives and overall direction.
What is the primary focus of Celularity?
Celularity is dedicated to developing placental-derived allogeneic cell therapies and advanced biomaterial products that target aging-related diseases and immune disorders.
What are MLASCs in relation to Celularity?
Mesenchymal-like adherent stromal cells (MLASCs) are a key cell type utilized by Celularity in their regenerative medicine therapies.
How can I contact Celularity for more information?
For investor inquiries, you can reach Carlos Ramirez at Carlos.ramirez@celularity.com. For media inquiries, please contact Raquel Cona or Michaela Fawcett at rcona@kcsa.com or mfawcett@kcsa.com, respectively.
